On February 22, 2010, Judge Thomas W. Thrash, Jr. dismissed the Federal Trade Commission’s (FTC) antitrust lawsuit alleging that Solvay Pharmaceuticals (Solvay) conspired with generic drug makers Watson Pharmaceuticals (Watson) and Par Pharmaceuticals (Par) to delay generic competition for the leading testosterone gel product Androgel. [1] The ruling represents a setback to the FTC’s aggressive campaign against so-called “pay-for-delay” patent settlements. Background The Androgel litigation challenges the settlement of patent litigation between branded drug manufacturer Solvay and generic drug producers Watson and Par (together, the defendants) relating to Solvay’s patent covering Androgel. Pursuant to the defendants’
Share on
|
|
The US District Court for the Northern District of Georgia dismisses the FTC’s pay-for-delay antitrust lawsuit ruling that the contested settlements are not an unreasonable restraint of trade (Androgel)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
